Thermo Fisher Scientific's new PPD clinical research laboratory building in Wisconsin will create 350 new jobs for scientists, adding to a workforce of nearly 2,300 at the facility, the company announced.
At 72,500 square feet, the new lab in Middleton increases chemistry, manufacturing, and control (CMC) analytical capabilities as part of its clinical development and laboratory services, according to Thermo Fisher. The site provides analytical services for small molecules and biologics, including biopharmaceuticals, inhaled pharmaceuticals, and device testing, cell and gene therapy, protein characterization, and mass spectrometry analysis for all phases of drug development.
In February, Thermo Fisher announced that it would add biosafety level 2 testing to address a growing need for biosafety testing for new cell and gene therapy targets and, in particular, testing for mycoplasma, as well as reducing the turnaround time for results.
The latest addition to the campus provides provides a multiuse and flexible biosafety level 2 laboratory that includes a liquid chromatography-mass spectrometry and protein characterization space, two large molecular suites with access-controlled pre- and post-amplification labs, and two large general-use labs, according to Thermo Fisher.
"With the addition of biosafety testing to its good manufacturing practices (GMP) portfolio of services at the Middleton facility, as well as the addition of the new building, the site offers a full complement of end-to-end laboratory services," Thermo Fisher said.
Thermo Fisher acquired PPD for $17.4 billion in 2021.
